Jubilant Pharmova expands Canadian radiopharma plant

Jubilant Pharmova is investing CAD 94.5 million to double the production capacity of its RUBY-FILL cardiac imaging agent in Canada. The project is backed by CAD 23.8 million in non-dilutive government funding, securing a high-margin growth engine. The expansion at the Kirkland, Québec facility targets a customer base that has doubled over the last three years. This matters because it aligns supply with proven, non-speculative demand in the high-barrier radiopharmaceuticals market. I am watching the Q3 FY27 earnings call for the exact timeline of the facility's modernization completion and the sequential margin impact of the CAD 23.8 million grant on the project's return on capital. The market often prices Jubilant Pharmova purely on its domestic API and CDMO volatility. What the consensus misses is the structural margin defense and valuation premium this specific expansion offers. Step one: RUBY-FILL operates in a high-barrier nuclear medicine niche with inelastic demand. Step two: doubling capacity captures the entire upside of a customer base that has already doubled, without proportional capex bloat. Step three: the CAD 23.8 million government grant acts as a direct subsidy, mechanically boosting the internal rate of return (IRR) and shielding the parent's balance sheet from foreign currency capex drag. The market views this as routine overseas capex, ignoring it is a highly subsidized, de-risked moat expansion. Accumulate for long-term high-margin radiopharma growth. Disclosure: I do not hold positions in this stock. This is for educational purposes only and does not constitute investment advice.